Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 15;13(9):4277-4287.
eCollection 2023.

Comparison of clinical efficacy between chrono-chemotherapy and conventional chemotherapy in patients with non-small cell lung cancer

Ziying Shang  1 , Juan Li  2
Affiliations

Comparison of clinical efficacy between chrono-chemotherapy and conventional chemotherapy in patients with non-small cell lung cancer

Ziying Shang et al. Am J Cancer Res. .

Abstract

This work focused on the clinical efficacy of chrono-chemotherapy and conventional chemotherapy on patients with non-small cell lung cancer (NSCLC), providing a theoretical basis for the clinical promotion of chrono-chemotherapy. 60 NSCLS patients in our hospital were randomly enrolled into a chrono-chemotherapy group and a conventional chemotherapy group, with 30 cases in each. Patients were treated with the standardized first-line treatment TP regimen (paclitaxel + cisplatin). After two cycles of chemotherapy, the clinical efficacy and adverse reactions of patients receiving various methods were observed. After the chemotherapy, CD3+, CD4+, and CD28+ increased while NK cells, B cells, and CD28- decreased in the conventional chemotherapy group (P<0.05); CD3+, CD4+, CD4+CD8+, B cells, and CD28+ increased while CD8+, NK cells, and CD28- decreased in chrono-chemotherapy group (P<0.05). The progression-free survival (PFS) of patients in the chrono-chemotherapy group (3.29 ± 0.46 years vs 2.56 ± 0.35 years) was longer (P<0.05). The quality of life (QOL) score in the chrono-chemotherapy group was higher (64.83 ± 1.54 points vs 51.72 ± 1.89 points) (P<0.05). The incidences of leukopenia (63.33%) and nausea and vomiting (53.33%) in the conventional chemotherapy group were higher than those in the chrono-chemotherapy group (30.00% and 30.00, respectively) (P<0.05). The chrono-chemotherapy could improve the cellular immune function of NSCLS patients, prolong their survival period, elevate the QOL, and reduce the side effects.

Keywords: Chrono-chemotherapy; cellular immunity; chrono-pharmacology; clinical efficacy; non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Immune function of patients. A: Lymphocytes CD3+; B: Lymphocytes CD4+; C: Lymphocytes CD8+; D: CD4+/CD8+; E: NK cells; F: B cells; G: Lymphocytes CD28+; H: Lymphocytes CD28-. Note: * indicated P<0.05 vs the levels before treatment.
Figure 2
Figure 2
Comparison of PFS and QOL scores. A: Comparison of PFS; B: Comparison of QOL score. Note: * indicated P<0.05 vs conventional chemotherapy group.
See this image and copyright information in PMC

References

    1. Xiao H. MiR-7-5p suppresses tumor metastasis of non-small cell lung cancer by targeting NOVA2. Cell Mol Biol Lett. 2019;24:60. - PMC - PubMed
    1. Zhang L, Wang J, Zhu B. Effect of single-hole thoracoscopic segmental pneumonectomy on perioperative immune function in patients with lung cancer. Acta Medica Mediterrane. 2022;38:843.
    1. Tandberg DJ, Tong BC, Ackerson BG, Kelsey CR. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: a comprehensive review. Cancer. 2018;124:667–678. - PubMed
    1. Remark R, Becker C, Gomez JE, Damotte D, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH, Powell CA, Altorki NK, Merad M, Gnjatic S. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med. 2015;191:377–390. - PMC - PubMed
    1. Chaudhary S, Singh A, Kumar P, Kaushik M. Strategic targeting of non-small-cell lung cancer utilizing genetic material-based delivery platforms of nanotechnology. J Biochem Mol Toxicol. 2021;35:e22784. - PubMed

LinkOut - more resources